CardioDx, the heart disease test developer that delayed plans to go public in November due to poor market conditions, has decided to test the IPO waters again. This time it will be doing it with some new leadership.
CardioDx is promoting yet another post-marketing study whose data may help the company's gene expression test for obstructive coronary artery disease reach more patients, better compete with the standard of care build and also build vital market share.
CardioDx, a cardiovascular genomic diagnostics company, pulled in an impressive $58 million in new equity financing in a massive round that attracted a Singapore investment firm and lured 14 previous backers.
CardioDx saw good news from Florida this week with the presentation of results from the COMPASS trial involving Corus CAD, a blood-based gene expression test for obstructive coronary artery disease.